Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Best Growth Stocks In The S&P 500
by Brian Bolan
Growth is hard to find in this market, but here is a list of four big caps still growing revenues.
Best Growth Stocks In The S&P 500
by Brian Bolan
Growth is challenged right now, but these large caps are still increasing revenues in a big way.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
PEG Ratio vs. the P/E Ratio
by Kevin Matras
Kevin Matras compares the PEG ratio to the P/E ratio and shows how to use them both for finding classically undervalued stocks with market beating growth rates. Highlighted stocks include CALM, EXPR, TSO, BBW and GILD.
What is Your Stock's Earnings Yield?
by Kevin Matras
This week, Kevin Matras talks about a stock's Earnings Yield and how to use it. Highlighted stocks include GILD, GT, KRA, ACM and TNK.
PEG Ratio vs. the P/E Ratio
by Kevin Matras
Kevin Matras compares the PEG ratio to the P/E ratio and shows how to use them both for finding classically undervalued stocks with market beating growth rates. Highlighted stocks include OUTR, GILD, LIOX, SIMO and WNC.
Retail Sector in the Spotlight
by Sheraz Mian
The retail environment is difficult, with consumers hesitant to spend their energy savings.
Retail Sector in the Spotlight
by Sheraz Mian
The retail environment is difficult, with consumers hesitant to spend their energy savings.
R-Squared Growth Rate: You Need to Know This
by Kevin Matras
Kevin Matras writes about the R-Squared Growth Rate and how it can help you find outperforming stocks. Highlighted stocks include GILD, C and BCS.
Standout Sectors of Q1 Earnings Season
by Sheraz Mian
The earnings picture emerging from the Q1 earnings season has been very bad.
Standout Sectors of Q1 Earnings Season
by Sheraz Mian
The earnings picture emerging from the Q1 earnings season has been very bad.
Q1 Earnings Scorecard - The Dollar Impact
by Sheraz Mian
Small-cap stocks do have an advantage in limited exposure to the strong U.S. dollar.
Q1 Earnings Season Ramps Up
by Sheraz Mian
We have enough bellwethers from other sectors to give us a good sense of this earnings season.
Q1 Earnings Season in Spotlight as Alcoa (AA) Reports Results
by Sheraz Mian
Market participants will be looking for Alcoa's commentary about the state of global aluminum demand.
What to Look for This Earnings Season
by Sheraz Mian
Earnings growth has turned negative for the first half of the year and remains barely in the positive territory in the back half.
What to Look for This Earnings Season
by Sheraz Mian
Earnings growth has turned negative for the first half of the year and remains barely in the positive territory in the back half.
Previewing the Q1 Earnings Season
by Sheraz Mian
Is the earnings picture really as bad as some are suggesting it is?
Q2 Earnings Season in Rearview Mirror
by Sheraz Mian
Q2's earnings growth strength has been broad-based and driven by top-line gains.
Record Earnings & Stronger Growth in Q2
by Sheraz Mian
The 2014 Q2 earnings season is moving towards the finish line.
Strong Earnings Season Winding Down
by Sheraz Mian
It's been tough for the retailers in recent quarters and Q2 is no different.
What is Your Stock's Earnings Yield?
by Kevin Matras
Kevin Matras talks about a stock's Earnings Yield and how to use it. Highlighted stocks include GILD, LYB, MGA, RFMD and UAL.
Q3 Earnings Estimates Not Falling As Much
by Sheraz Mian
The reduced negative revisions rate at this stage in the reporting cycle is the most notable positive element of this earnings season.
Can the Earnings Rebound be Sustained?
by Sheraz Mian
The 2014 Q2 earnings season is presenting a much improved picture.